Patents by Inventor Mark S. Fineman

Mark S. Fineman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biguanide Compositions and Methods of Treating Metabolic Disorders
    Publication number: 20170209394
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: October 31, 2016
    Publication date: July 27, 2017
    Inventors: Alain D. BARON, Mark S. FINEMAN, Nigel R.A. BEELEY
  • Biguanide Compositions and Methods of Treating Metabolic Disorders
    Publication number: 20170202790
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: October 31, 2016
    Publication date: July 20, 2017
    Inventors: Alain D. BARON, Mark S. FINEMAN, Nigel R.A. BEELEY
  • Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk
    Publication number: 20170165209
    Abstract: Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 15, 2017
    Inventors: Alain D. BARON, Mark S. FINEMAN, Nigel R.A. BEELEY
  • Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
    Patent number: 9572784
    Abstract: Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 21, 2017
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Chemosensory Receptor Ligand-Based Therapies
    Publication number: 20170020829
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Alain D. BARON, Nigel R.A. BEELEY, Mark S. FINEMAN
  • Chemosensory receptor ligand-based therapies
    Patent number: 9486463
    Abstract: Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: November 8, 2016
    Assignee: AMBRA BIOSCIENCE LLC
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R. G. Jones, Mark S. Fineman
  • Biguanide compositions and methods of treating metabolic disorders
    Patent number: 9481642
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 1, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Biguanide compositions and methods of treating metabolic disorders
    Patent number: 9480663
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 1, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Chemosensory receptor ligand-based therapies
    Patent number: 9463170
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 11, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Nigel R. A. Beeley, Mark S. Fineman
  • Compositions and Methods for Treating Metabolic Disorders
    Publication number: 20160095828
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Inventors: Alain D. BARON, Mark S. FINEMAN, Nigel R. A. BEELEY
  • Compositions and methods of treating metabolic disorders
    Patent number: 9211263
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Grant
    Filed: January 5, 2013
    Date of Patent: December 15, 2015
    Assignee: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Chemosensory Receptor Ligand-Based Therapies
    Publication number: 20150265555
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: June 8, 2015
    Publication date: September 24, 2015
    Inventors: Alain D. BARON, Nigel R.A. BEELEY, Mark S. FINEMAN
  • Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk
    Publication number: 20150196509
    Abstract: Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.
    Type: Application
    Filed: July 11, 2013
    Publication date: July 16, 2015
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Chemosensory receptor ligand-based therapies
    Patent number: 9050292
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: June 9, 2015
    Assignee: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R. G. Jones, Nigel R. A. Beeley, Mark S. Fineman
  • Biguanide Compositions and Methods of Treating Metabolic Disorders
    Publication number: 20150064223
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: July 11, 2012
    Publication date: March 5, 2015
    Applicant: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Compositions and Methods for Treating Metabolic Disorders
    Publication number: 20150065578
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Application
    Filed: January 5, 2013
    Publication date: March 5, 2015
    Inventors: Alain D. Baron, Mark S. Fineman, Niger R.A. Beeley
  • Biguanide Compositions and Methods of Treating Metabolic Disorders
    Publication number: 20140341986
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Biguanide compositions and methods of treating metabolic disorders
    Patent number: 8796338
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 5, 2014
    Assignee: Elcelyx Therapeutics, Inc
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Compositions and Methods for Treating Metabolic Disorders
    Publication number: 20140193498
    Abstract: Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.
    Type: Application
    Filed: January 3, 2014
    Publication date: July 10, 2014
    Inventors: Alain D. BARON, Mark S. FINEMAN, Terri KIM, Stephen Kwaku DORDUNOO
  • Chemosensory Receptor Ligand-Based Therapies
    Publication number: 20140030332
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: January 6, 2012
    Publication date: January 30, 2014
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Mark S. Fineman